LEVAQUIN by Johnson & Johnson is [see microbiology(12. Approved for moderate, severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section, nosocomial pneumonia due to methicillinsusceptible staphylococcus aureus and 36 more indications. First approved in 2004.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
LEVAQUIN (levofloxacin) is a fluoroquinolone antibiotic administered orally or intravenously that treats moderate-to-severe bacterial infections across respiratory, skin, urinary, and systemic indications. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication in susceptible gram-positive and gram-negative organisms. The drug demonstrates rapid and nearly complete oral absorption (99% bioavailability) with linear, predictable pharmacokinetics across dosing regimens.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and shift toward generic optimization or portfolio reallocation.
[see Microbiology(12.4)]. 12.3 Pharmacokinetics The mean ±SD pharmacokinetic parameters of levofloxacin determined under single and steady-state conditions following oral tablet, oral solution, or intravenous (IV) doses of levofloxacin are summarized in Table 8. Table 8: Mean ±SD Levofloxacin PK…
Worked on LEVAQUIN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LEVAQUIN careers offer limited growth trajectory given LOE-approaching lifecycle stage and zero linked job activity. Roles focus on maximizing remaining patent-protected revenue, managing competitive displacement, and preparing for generic transition. Positions are primarily in field sales and hospital sales, with declining headcount expectations.